Digoxin and hypokalemia

Reading File

Finding Sources

Searching PubMed

digoxin toxicity hypokalemia

Reading File

Finding Sources

Searching Images

digoxin toxicity ECG arrhythmia

A standard 12-lead diagnostic electrocardiogram (ECG) printed on grid paper, demonstrating key clinical features of cardiac glycoside toxicity. The tracing shows a sinus rhythm with a prolonged PR interval, indicative of a first-degree atrioventricular (AV) block. There is widespread, persistent ST-segment depression, most prominent in the precordial leads (V1 through V6), characterized by a down-sloping morphology often described as the 'digoxin effect.' Associated with this depression are biphasic T-waves across multiple leads. These findings represent a transition from a higher-degree heart block to a more stable conduction pattern following the administration of digoxin immune fab. The educational focus of this image is the recognition of ECG changes associated with cardiotoxic glycosides (e.g., Cerbera odollam or digoxin) and the assessment of treatment response in a clinical toxicology or emergency medicine context.

A 12-lead electrocardiogram (ECG) demonstrating a broad complex tachycardia with distinct morphological variations across the leads. In the limb leads (I, II, III, aVR, aVL, aVF) and some precordial leads (V1, V5, V6), the rhythm appears irregularly irregular with narrow to slightly widened QRS complexes and absent P waves, consistent with atrial fibrillation and possible aberrant conduction. However, in leads V2, V3, and V4, the tracing transitions into a regular, wide-complex rhythm characterized by bizarre, sharply peaked, and uniform QRS complexes with a rapid steep descent. The morphology in these specific leads is suggestive of bidirectional ventricular tachycardia or a ventricular origin. This visual comparison illustrates the transition between a supraventricular arrhythmia (atrial fibrillation) and a more organized wide-complex ventricular rhythm, potentially related to digoxin toxicity or cardiac electrophysiological instability. The educational focus is on rhythm recognition, QRS morphology analysis, and the identification of potentially life-threatening ventricular arrhythmias.

This diagnostic image is a 12-lead electrocardiogram (ECG) demonstrating a ventricular-paced rhythm. The tracing shows a consistent pattern across all leads (I-III, aVR-aVF, and V1-V6) characterized by sharp, vertical pacing artifacts (spikes) immediately preceding each QRS complex. The QRS complexes are significantly widened with a bundle branch block-like morphology, typical of ventricular depolarization originating from an artificial pacemaker electrode. In the inferior leads (II, III, aVF), the pacing spikes appear as sharp downward deflections followed by broad, slurred QRS complexes and discordant T waves. Notably, there is an absence of discernible P waves preceding the pacing spikes, indicating an underlying rhythm managed by ventricular pacing. This ECG was obtained 24 hours following treatment with Digoxin Immune Fab (DIF) for digoxin toxicity, illustrating the conversion from an unstable arrhythmia to a stable, paced rhythm in a patient with heart failure.

Here is a complete overview of the digoxin-hypokalemia relationship, drawing from multiple authoritative sources.

Digoxin and Hypokalemia

Mechanism

Digoxin works by inhibiting the Na+/K+-ATPase pump on cardiac myocytes. Potassium (K+) and digoxin compete for the same binding sites on this enzyme. When serum K+ is low (hypokalemia), fewer K+ ions are available to compete, so digoxin binds more avidly - producing an intensified pharmacological effect even at "therapeutic" serum digoxin concentrations.

As Harrison's Principles (22nd ed., 2025) explains:

"Hypokalemia predisposes to digoxin toxicity by a number of mechanisms, including reduced competition between K+ and digoxin for shared binding sites on cardiac Na+/K+-ATPase subunits."

Goldman-Cecil Medicine, p. 626

Clinical Significance

Factor	Effect
Hypokalemia (K+ < 3.5 mEq/L)	Enhances digoxin binding → toxicity at "normal" levels
Hypomagnesemia (co-exists with hypokalemia)	Additional risk factor; also exacerbates Na+/K+-ATPase inhibition
Diuretic use	Causes both hypokalemia AND reduces digoxin clearance via dehydration

A classic clinical scenario (Tintinalli's Emergency Medicine): A patient on digoxin is started on a diuretic - this causes mild dehydration (reducing digoxin clearance) AND hypokalemia (increasing digoxin sensitivity), resulting in chronic toxicity even without any dose change.

ECG Changes in Digoxin Toxicity

Therapeutic "digoxin effect" (not toxicity):

Scooped/sagging ST-segment depression
T-wave flattening or inversion
QT interval shortening
Increased U-wave amplitude

Toxic arrhythmias (almost any arrhythmia can occur, except rapidly conducted atrial arrhythmias):

Premature ventricular contractions (most common)
Bradycardic rhythms (heart block)
Bidirectional ventricular tachycardia (rare but highly characteristic)

Here is an ECG showing the "digoxin effect" with ST depression and the cardiac glycoside toxicity pattern:

ECG showing digoxin toxicity with ST depression and AV block

Bidirectional ventricular tachycardia - characteristic ECG of severe digoxin toxicity

Acute vs. Chronic Toxicity

Feature	Acute Toxicity	Chronic Toxicity
Typical patient	Intentional overdose	Elderly, on diuretics
Potassium	Hyperkalemia (generalized ATPase blockade)	Hypokalemia (predisposing factor)
Symptoms	Prominent GI (nausea, vomiting)	Vague - fatigue, confusion, weakness
Arrhythmias	Bradyarrhythmias common	Ventricular arrhythmias more frequent

Key point on K+ in poisoning:

In acute overdose: hyperkalemia develops from generalized Na+/K+-ATPase blockade and is a marker of severity. K+ >5.0 mEq/L is an indication for antidote administration.
In chronic toxicity: hypokalemia is the predisposing factor that should be corrected.

Management of Hypokalemia in Digoxin Toxicity

Correct hypokalemia - especially in chronic toxicity; this reduces myocardial sensitivity to digoxin
Correct hypomagnesemia - must replete Mg2+ to successfully correct K+ (hypomagnesemia causes refractory hypokalemia)
Target K+ >4.0 mEq/L in patients on digoxin (Morgan & Mikhail's Clinical Anesthesiology recommends plasma K+ values above 4 mEq/L in digoxin patients)
Digoxin-specific Fab fragments (Digifab/Digibind) - treatment of choice for life-threatening toxicity; indicated for:
- Life-threatening dysrhythmias
- Severe bradycardia/heart block unresponsive to atropine
- Hyperkalemia >5.0 mEq/L in acute poisoning
- Hemodynamic instability

Drugs That Worsen the Interaction

Several drugs increase digoxin levels OR worsen hypokalemia, compounding the risk:

Loop/thiazide diuretics - cause hypokalemia directly
Amiodarone, verapamil, diltiazem - increase serum digoxin concentrations
Erythromycin - increases digoxin absorption by altering gut flora
Quinidine - displaces digoxin from binding sites, increases levels

Summary

Hypokalemia is the single most clinically important electrolyte abnormality that potentiates digoxin toxicity. The mechanism is direct competition at the Na+/K+-ATPase binding site. In practice, any patient on digoxin who starts a diuretic needs close monitoring of K+ levels, with a target serum K+ of 4.0-5.0 mEq/L for maximum safety.

Sources: Goldman-Cecil Medicine | Harrison's Principles of Internal Medicine, 22e | Tintinalli's Emergency Medicine | Washington Manual of Medical Therapeutics | Morgan & Mikhail's Clinical Anesthesiology

Corrected reticulocyte count

Finding Sources

Searching Images

reticulocyte count correction anemia classification diagram

This pathophysiology diagram illustrates the multifactorial causes and consequences of anemia in patients with heart failure (HF) and a left ventricular assist device (LVAD). The top section identifies contributors to anemia, including chronic gastrointestinal (GI) bleeding secondary to aspirin use, systemic anticoagulation, arteriovenous (AV) malformations, and von Willebrand disease. Other contributing factors shown are uremic gastritis, iron (Fe2+) malabsorption, and persistent right ventricular failure. Central to the diagram is the manifestation of anemia (defined as Hemoglobin < 12 g/dL), which correlates with elevated creatinine, decreased albumin, and increased mortality. The diagram also highlights therapeutic interventions such as erythropoiesis-stimulating agents (ESAs), aspirin-free antithrombotic management, omega-3 fatty acids, and low-intensity anticoagulation. Successful therapy is depicted as leading to normal red blood cell (RBC) counts, resolution of heart failure symptoms, and reduced mortality. The role of erythropoietin (EPO) is also noted in the context of LVAD-related anemia management.

This medical infographic summarizes the clinical outcomes associated with baseline anemia in patients undergoing Transcatheter Mitral Valve Repair (TMVr). The diagram illustrates a cohort analysis of US procedures from 2011 to 2015, categorizing 4,382 total patients into two groups: 978 with anemia (represented by a red blood cell cluster) and 3,404 without anemia. A central flow arrow directs the viewer to the adverse outcomes significantly associated with the anemic group. These complications are visually depicted through icons and labels, including Acute Kidney Injury (AKI) represented by a renal system silhouette, Blood Transfusions shown with a blood bag icon, Pericardial Complications illustrated by a heart with a pericardiocentesis needle, and increased healthcare utilization (Length of Stay and Hospital Charges) represented by a hospital building icon. This clinical algorithm serves as a summary of the impact of pre-procedural anemia on postoperative morbidity and hospital resource management in cardiovascular medicine.

Reading File

Excellent - rich content from multiple sources. Here is the complete breakdown.

Corrected Reticulocyte Count

Why Correction Is Needed

The raw reticulocyte percentage is misleading in anemia. When a patient is anemic, total RBC count is lower - so even a normal absolute number of reticulocytes will appear as a falsely elevated percentage. Correction adjusts for this dilution effect.

Example: A patient produces the same 50 × 10⁹/L reticulocytes as normal, but with half the RBCs - the percentage reads 2% instead of 1%, falsely suggesting increased production.

Step 1 - Corrected Reticulocyte Count (CRC)

This corrects the reticulocyte % for the degree of anemia by comparing the patient's hematocrit (or hemoglobin) to normal.

Using Hematocrit:

$$\text{CRC} = \text{Reticulocyte %} \times \frac{\text{Patient Hct}}{45}$$

Using Hemoglobin:

$$\text{CRC} = \text{Reticulocyte %} \times \frac{\text{Patient Hb}}{15}$$

Normal CRC: 0.5-1.5% (same range as raw reticulocyte %)

Goldman-Cecil Medicine, Table 144-3

Step 2 - Reticulocyte Production Index (RPI)

The CRC still overestimates production in severe anemia because erythropoietin drives premature release of reticulocytes from the marrow ("shift reticulocytes"). These shift reticulocytes spend longer than 1 day in the blood before maturing, so each one is counted for more days than it represents in actual daily production.

The RPI corrects for this extended maturation time:

$$\text{RPI} = \frac{\text{CRC}}{\text{Maturation Factor}}$$

Maturation Factor Table

Hematocrit	Maturation Factor (days)
36-45%	1.0
26-35%	1.5
16-25%	2.0
≤15%	2.5

Quick Compendium of Clinical Pathology, 5th ed. | Goldman-Cecil Medicine, Table 144-3

The maturation factor only needs to be applied when shift reticulocytes (polychromatic macrocytes / nucleated RBCs) are visible on the blood film, indicating early marrow release.

Worked Example

A patient has:

Reticulocyte count: 7%
Hct: 25%
Shift reticulocytes visible on smear

Step 1 - CRC: 7% × (25/45) = 3.9%

Step 2 - RPI (Hct 25% → maturation factor 2.0): 3.9 / 2.0 = ~2.0

Interpretation: Marrow is producing approximately 2× normal red cells per day - an appropriate, but not maximal, response.

Henry's Clinical Diagnosis and Management by Laboratory Methods, p. 1909-1920

Interpretation of RPI

RPI	Interpretation	Cause
< 2	Hypoproliferative - inadequate marrow response	Iron deficiency, B12/folate deficiency, aplastic anemia, anemia of chronic disease, renal failure
2-3	Borderline / partially adequate
> 3	Hyperproliferative - appropriate bone marrow response	Hemolytic anemia, acute blood loss

A normal person can increase RBC production 2× within 1 week and up to 6-8× at maximum with adequate iron stores.

Absolute Reticulocyte Count

The simplest and most direct measure - no correction needed:

$$\text{Absolute Retic Count} = \text{Retic %} \times \text{RBC count}$$

Normal: 20,000-100,000/µL (or ~50 × 10⁹/L)

Many modern labs report this directly and it is increasingly preferred over the CRC/RPI because it avoids the assumptions built into correction formulas.

Summary Flow

Raw Retic %
    ↓ × (Patient Hct / 45)
Corrected Reticulocyte Count (CRC)
    ↓ ÷ Maturation Factor (if shift retics present)
Reticulocyte Production Index (RPI)

RPI < 2 → Hypoproliferative anemia (marrow failure/nutritional)
RPI > 3 → Hyperproliferative (hemolysis/blood loss)

Sources: Goldman-Cecil Medicine | Quick Compendium of Clinical Pathology, 5th ed. | Henry's Clinical Diagnosis and Management by Laboratory Methods

Fena

Finding Sources

Reading File

Finding Sources

Reading File

All the key data is gathered. Here is the complete breakdown.

FENa (Fractional Excretion of Sodium)

What It Measures

FENa expresses what fraction of filtered sodium is excreted in the urine, as a percentage of the amount filtered at the glomerulus. Since creatinine is freely filtered and not reabsorbed, it serves as a reference for GFR, allowing sodium reabsorption to be measured independently of urine flow rate.

Formula

$$\text{FENa (%)} = \frac{U_{Na} \times P_{Cr}}{P_{Na} \times U_{Cr}} \times 100$$

Where:

U = urine, P = plasma (serum)
Na = sodium, Cr = creatinine

Requires a spot urine sample - no timed collection needed.

Comprehensive Clinical Nephrology, 7th ed. | Washington Manual of Medical Therapeutics

Interpretation

FENa	Interpretation
< 1%	Prerenal AKI - tubules avidly reabsorbing Na (intact function)
1-2%	Indeterminate zone
> 2-3%	Intrinsic renal AKI (ATN) - tubules damaged, cannot reabsorb Na

Physiological basis: In prerenal states (hypovolemia, decreased effective arterial volume), aldosterone and angiotensin II drive avid tubular sodium reabsorption - almost none is "wasted" in urine. In ATN, tubular cells are injured and lose their ability to reabsorb sodium, so large amounts spill into urine despite volume depletion.

Quick Compendium of Clinical Pathology, 5th ed.

Urinary Indices Comparison Table (Prerenal vs. Intrinsic/ATN)

Parameter	Prerenal AKI	Intrinsic (ATN)
FENa	< 1%	> 2%
FEUrea	< 35%	> 35-50%
Urine Na	< 15-20 mEq/L	> 40 mEq/L
Urine osmolality	> 500 mOsm/kg	300-400 mOsm/kg (isosthenuria)
Urine specific gravity	> 1.020	< 1.010
BUN:Creatinine ratio	> 20:1	< 20:1
Urine sediment	Normal / hyaline casts	Muddy brown granular casts, tubular epithelial cells

Quick Compendium of Clinical Pathology, 5th ed.

Important Limitations - When FENa Misleads

False Low FENa (< 1%) DESPITE intrinsic AKI - suggests prerenal but is NOT:

Condition	Reason
Diuretic use	Diuretics cause natriuresis - FENa is falsely elevated, not applicable
Contrast nephropathy	Vasoconstriction mechanism; tubular injury with low FENa
Myoglobinuria / rhabdomyolysis	Tubular obstruction maintains some Na reabsorption
Hemoglobinuria	Same mechanism as myoglobinuria
Early sepsis-associated AKI	FENa can be low early in course
Acute glomerulonephritis	Volume depletion + intact tubules = low FENa despite intrinsic disease
Hepatorenal syndrome	Intense Na avidity despite functional AKI
Advanced cirrhosis / heart failure	Neurohormonal activation drives Na retention

False High FENa (> 2%) DESPITE prerenal - suggests ATN but is NOT:

Condition	Reason
Diuretic use	Forced natriuresis
CKD with salt-wasting	Baseline tubular dysfunction
Bicarbonaturia	Na excreted with bicarbonate (e.g., RTA, vomiting)
IV saline administration	Sodium loading
Glycosuria	Osmotic diuresis carries Na

"FENa has the most utility in oliguric patients who are not given diuretics." - Harrison's Principles of Internal Medicine, 22e

FEUrea - The Alternative in Diuretic Users

Because urea reabsorption (proximal tubule) is less affected by loop and thiazide diuretics than sodium reabsorption, FEUrea is preferred when the patient is on diuretics.

$$\text{FEUrea (%)} = \frac{U_{Urea} \times P_{Cr}}{BUN \times U_{Cr}} \times 100$$

FEUrea	Interpretation
< 35%	Prerenal AKI
> 35-50%	ATN

Sensitivity of FEUrea <35% for prerenal: 68-98%; specificity: 48-98%. Sensitivity of FENa <1% for prerenal: 58-96%; specificity: 75-95%.

Some studies show FEUrea is more sensitive than FENa in patients on diuretics.

Symptom to Diagnosis, 4th ed. | Harriet Lane Handbook, 23rd ed.

Special Population - Neonates/Infants

Infants have diminished tubular sodium reabsorption - the FENa threshold for volume depletion is <3% (not <1%) because their baseline FENa is higher.

Harriet Lane Handbook, 23rd ed.

Bonus: FEHCOз for RTA Typing

The same fractional excretion formula applied to bicarbonate helps classify renal tubular acidosis:

FEHCO₃	Interpretation
< 5%	Normal / Distal (Type I) RTA
> 15%	Proximal (Type II) RTA

Clinical Bottom Line

FENa is a useful tool for distinguishing prerenal from intrinsic AKI in oliguric, non-diuretic patients - but it has significant limitations and must always be interpreted alongside clinical context, urine microscopy, and the full clinical picture. Use FEUrea when diuretics confound the result.

This is a shared conversation. Sign in to Orris to start your own chat.